Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
← catalyst calendarNCT07052578 · readout in 834 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
400estimated
Sites
26
Country
Russia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-30 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Prostate Cancer
Primary outcomes
what the primary-completion date above is the date OFProportion of patients received any ADT
measured 36 months
Proportion of patients received ADT by each type and by each drug
measured 36 months
Proportion of patients received first generation antiandrogens
measured 36 months
Proportion of patients received androgen receptor pathway inhibitors (ARPI) at mHSPC
measured 36 months
Duration of ARPI therapy
measured 36 months
Proportion of patients received any chemotherapy at mHSPC
measured 36 months
Duration of chemotherapy
measured 36 months
Proportion of patients received radiation therapy
measured 36 months
Proportion of patients with each radiation area
measured 36 months
Proportion of patients underwent surgery at mHSPC
measured 36 months
Proportion of patients received triplet therapy at mHSPC
measured 36 months
Time from mPC diagnosis to progression to mCRPC
measured 36 months
Proportion of patients with each site of disease progression
measured 36 months
Testosterone level at the time of mCRPC
measured 36 months
Proportion of patients with presence of pathogenic mutations in HRR genes in ctDNA
measured 36 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed